{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T14:06:53Z","timestamp":1790604413501,"version":"4.1.0"},"reference-count":236,"publisher":"SAGE Publications","issue":"6","license":[{"start":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T00:00:00Z","timestamp":1694131200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JPD"],"published-print":{"date-parts":[[2023,9,8]]},"abstract":"<jats:p>Background: Multi-arm, multi-stage (MAMS) platform trials can accelerate the identification of disease-modifying treatments for Parkinson\u2019s disease (PD) but there is no current consensus on the optimal outcome measures (OM) for this approach. Objective: To provide an up-to-date inventory of OM for disease-modifying PD trials, and a framework for future selection of OM for such trials. Methods: As part of the Edmond J Safra Accelerating Clinical Trials in Parkinson Disease (EJS ACT-PD) initiative, an expert group with Patient and Public Involvement and Engagement (PPIE) representatives\u2019 input reviewed and evaluated available evidence on OM for potential use in trials to delay progression of PD. Each OM was ranked based on aspects such as validity, sensitivity to change, participant burden and practicality for a multi-site trial. Review of evidence and expert opinion led to the present inventory. Results: An extensive inventory of OM was created, divided into: general, motor and non-motor scales, diaries and fluctuation questionnaires, cognitive, disability and health-related quality of life, capability, quantitative motor, wearable and digital, combined, resource use, imaging and wet biomarkers, and milestone-based. A framework for evaluation of OM is presented to update the inventory in the future. PPIE input highlighted the need for OM which reflect their experience of disease progression and are applicable to diverse populations and disease stages. Conclusion: We present a range of OM, classified according to a transparent framework, to aid selection of OM for disease-modifying PD trials, whilst allowing for inclusion or re-classification of relevant OM as new evidence emerges.<\/jats:p>","DOI":"10.3233\/jpd-230051","type":"journal-article","created":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T15:08:00Z","timestamp":1690902480000},"page":"1011-1033","source":"Crossref","is-referenced-by-count":20,"title":["Outcome Measures for Disease-Modifying Trials in Parkinson\u2019s Disease: Consensus Paper by the EJS ACT-PD Multi-Arm Multi-Stage Trial Initiative"],"prefix":"10.1177","volume":"13","author":[{"given":"Cristina","family":"Gonzalez-Robles","sequence":"first","affiliation":[{"name":"University College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the EJS ACT-PD Consortium BarkerRoger CarpenterJames Ben ShlomoYoav EdwardsMark WhoneAlan CounsellCarl SalathielDorothy WhippsSue JewellAnna GrosPriti BarberTom Haar MilloShlomi ChaudhuriK Ray SchapiraAnthony HV BandmannOliver StottSimon TofarisGeorge SammlerEsther MortiboysHeather WeiLi WongAlan DutySusan DexterDavid ScurfieldPaula MartinKeith JabbariEdwin MullinStephen MorrisHuw BreenDavid LambertChristian KorliparaPrasad SilverdaleMonty BhatiaKailash YarnallAlison KhengarRaj CollinsHelen Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rimona S.","family":"Weil","sequence":"additional","affiliation":[{"name":"University College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"van Wamelen","sequence":"additional","affiliation":[{"name":"King\u2019s College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mich\u00e8le","family":"Bartlett","sequence":"additional","affiliation":[{"name":"Expert by experience, Guildford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Burnell","sequence":"additional","affiliation":[{"name":"Medical Research Council Clinical Trials Unit at University College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline S.","family":"Clarke","sequence":"additional","affiliation":[{"name":"University College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele T.","family":"Hu","sequence":"additional","affiliation":[{"name":"University of Oxford, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brook","family":"Huxford","sequence":"additional","affiliation":[{"name":"Queen Mary University of London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashwani","family":"Jha","sequence":"additional","affiliation":[{"name":"University College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Lambert","sequence":"additional","affiliation":[{"name":"University College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Lawton","sequence":"additional","affiliation":[{"name":"University of Bristol, Bristol, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgia","family":"Mills","sequence":"additional","affiliation":[{"name":"University College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alastair","family":"Noyce","sequence":"additional","affiliation":[{"name":"Queen Mary University of London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Piccini","sequence":"additional","affiliation":[{"name":"Imperial College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuhan","family":"Pushparatnam","sequence":"additional","affiliation":[{"name":"Expert by experience, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynn","family":"Rochester","sequence":"additional","affiliation":[{"name":"Newcastle University, Newcastle, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carroll","family":"Siu","sequence":"additional","affiliation":[{"name":"Expert by experience, Canterbury, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline H.","family":"Williams-Gray","sequence":"additional","affiliation":[{"name":"University of Cambridge, Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Louise","family":"Zeissler","sequence":"additional","affiliation":[{"name":"University of Plymouth, Plymouth, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Zetterberg","sequence":"additional","affiliation":[{"name":"University of Gothenburg, M\u00f6lndal, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille B.","family":"Carroll","sequence":"additional","affiliation":[{"name":"University of Plymouth, Plymouth, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Foltynie","sequence":"additional","affiliation":[{"name":"University College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anette","family":"Schrag","sequence":"additional","affiliation":[{"name":"University College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","reference":[{"key":"10.3233\/JPD-230051_ref1","doi-asserted-by":"crossref","first-page":"945398","DOI":"10.3389\/fnins.2022.945398","article-title":"Measurement tools to assess activities of daily living in patients with Parkinson\u2019s disease: A systematic review","volume":"16","author":"Bou\u00e7a-Machado","year":"2022","journal-title":"Front Neurosci"},{"key":"10.3233\/JPD-230051_ref2","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1080\/14737167.2021.1841638","article-title":"Tools to assess the quality of life in patients with Parkinson\u2019s disease: A systematic review","volume":"21","author":"Berardi","year":"2021","journal-title":"Expert Rev Pharmacoeconomics Outcomes Res"},{"key":"10.3233\/JPD-230051_ref3","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1177\/1740774512438980","article-title":"National Institute of Neurological Disorders and Stroke Common Data Element Project - approach and methods","volume":"9","author":"Grinnon","year":"2012","journal-title":"Clin Trials"},{"key":"10.3233\/JPD-230051_ref4","unstructured":"National Institute of Neurological Disorders and Stroke (2022) Parkinson\u2019s Disease NINDS Common Data Elements. Retrieved 12\/01\/2023 from: https:\/\/www.commondataelements.ninds.nih.gov\/Parkinson\u2019s%20Disease"},{"key":"10.3233\/JPD-230051_ref5","doi-asserted-by":"crossref","first-page":"715","DOI":"10.3233\/JPD-202346","article-title":"People with Parkinson\u2019s disease: What symptoms do they most want to improve and how does this change with disease duration?","volume":"11","author":"Port","year":"2021","journal-title":"J Parkinsons Dis"},{"key":"10.3233\/JPD-230051_ref6","unstructured":"An EPDA-UCB survey to better understand the challenges of living with Parkinson\u2019s, https:\/\/www.parkinsonseurope.org\/media\/2301\/an-epda-ucb-survey-to-better-understand-the-challenges-of-living-with-parkinsons.pdf"},{"key":"10.3233\/JPD-230051_ref7","unstructured":"Guy W (1976) ECDEU Assessment Manual for Psychopharmacology. US Department of Health, Education, and Welfare Public Health Service Alcohol, Drug Abuse, and Mental Health Administration, Rockville, MD."},{"key":"10.3233\/JPD-230051_ref8","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1002\/mds.23429","article-title":"Systematic review of levodopa dose equivalency reporting in Parkinson\u2019s disease","volume":"25","author":"Tomlinson","year":"2010","journal-title":"Mov Disord"},{"key":"10.3233\/JPD-230051_ref9","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1212\/WNL.17.5.427","article-title":"Parkinsonism: Onset, progression, and mortality","volume":"17","author":"Hoehn","year":"1967","journal-title":"Neurology"},{"key":"10.3233\/JPD-230051_ref10","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1002\/mds.22340","article-title":"Movement Disorder Society-sponsored revision of the Unified Parkinson\u2019s Disease Rating Scale (MDS-UPDRS): Scale presentation and clinimetric testing results","volume":"23","author":"Goetz","year":"2008","journal-title":"Mov Disord"},{"key":"10.3233\/JPD-230051_ref11","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.parkreldis.2012.10.008","article-title":"Potential reliability and validity of a modified version of the Unified Parkinson\u2019s Disease Rating Scale that could be administered remotely","volume":"19","author":"Abdolahi","year":"2013","journal-title":"Parkinsonism Relat Disord"},{"key":"10.3233\/JPD-230051_ref12","doi-asserted-by":"crossref","first-page":"4802570","DOI":"10.1155\/2016\/4802570","article-title":"Remotely assessing symptoms of Parkinson\u2019s disease using videoconferencing: A feasibility study","volume":"2016","author":"Stillerova","year":"2016","journal-title":"Neurol Res Int"},{"key":"10.3233\/JPD-230051_ref13","first-page":"2920255","article-title":"Abbreviated MDS-UPDRS for remote monitoring in PD identified using exhaustive computational search","volume":"2022","author":"Morinan","year":"2022","journal-title":"Parkinsons Dis"},{"key":"10.3233\/JPD-230051_ref14","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3233\/JPD-2011-0002","article-title":"The factor structure of the UPDRS as an index of disease progression in Parkinson\u2019s disease","volume":"1","author":"Evans","year":"2011","journal-title":"J Parkinsons Dis"},{"key":"10.3233\/JPD-230051_ref15","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1002\/mds.22341","article-title":"The unified dyskinesia rating scale: Presentation and clinimetric profile","volume":"23","author":"Goetz","year":"2008","journal-title":"Mov Disord"},{"key":"10.3233\/JPD-230051_ref16","unstructured":"ProFaNE Prevention of Falls Network Earth \u2013 Definition of a Fall, http:\/\/profane.co\/2012\/02\/22\/definition-of-a-fall\/."},{"key":"10.3233\/JPD-230051_ref17","doi-asserted-by":"crossref","first-page":"323","DOI":"10.2340\/16501977-0537","article-title":"Using psychometric techniques to improve the balance evaluation systems test: The mini-bestest","volume":"42","author":"Franchignoni","year":"2010","journal-title":"J Rehabil Med"},{"key":"10.3233\/JPD-230051_ref18","unstructured":"Miranda-Cantellops N , Tiu TK (2023) Berg Balance Testing. StatPearls [Internet], StatPearls Publishing, Treasure Island (FL)."},{"key":"10.3233\/JPD-230051_ref19","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1093\/geronj\/45.6.P239","article-title":"Falls efficacy as a measure of fear of falling","volume":"45","author":"Tinetti","year":"1990","journal-title":"J Gerontol"},{"key":"10.3233\/JPD-230051_ref20","doi-asserted-by":"crossref","first-page":"M28","DOI":"10.1093\/gerona\/50A.1.M28","article-title":"The Activities-specific Balance Confidence (ABC) scale","volume":"50A","author":"Powell","year":"1995","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"10.3233\/JPD-230051_ref21","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s004550010012","article-title":"The SWAL-QOL outcomes tool for oropharyngeal dysphagia in adults: I. Conceptual foundation and item development","volume":"15","author":"McHorney","year":"2000","journal-title":"Dysphagia"},{"key":"10.3233\/JPD-230051_ref22","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1007\/s004550010013","article-title":"The SWAL-QOL outcomes tool for oropharyngeal dysphagia in adults: II. Item reduction and preliminary scaling","volume":"15","author":"McHorney","year":"2000","journal-title":"Dysphagia"},{"key":"10.3233\/JPD-230051_ref23","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s00455-001-0109-1","article-title":"The SWAL-QOL and SWAL-CARE outcomes tool for oropharyngeal dysphagia in adults: III. Documentation of reliability and validity","volume":"17","author":"McHorney","year":"2002","journal-title":"Dysphagia"},{"key":"10.3233\/JPD-230051_ref24","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s00455-005-0026-9","article-title":"Clinical validity of the SWAL-QOL and SWAL-CARE outcome tools with respect to bolus flow measures","volume":"21","author":"McHorney","year":"2006","journal-title":"Dysphagia"},{"key":"10.3233\/JPD-230051_ref25","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1002\/mds.21362","article-title":"Simple clinical tests may predict severe oropharyngeal dysphagia in Parkinson\u2019s disease","volume":"22","author":"Lam","year":"2007","journal-title":"Mov Disord"},{"key":"10.3233\/JPD-230051_ref26","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1016\/j.apmr.2011.02.011","article-title":"Reproducibility and validity of patient-rated assessment of speech, swallowing, and saliva control in parkinson\u2019s disease","volume":"92","author":"Kalf","year":"2011","journal-title":"Arch Phys Med Rehabil"},{"key":"10.3233\/JPD-230051_ref27","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1097\/00002826-200003000-00003","article-title":"A home diary to assess functional status in patients with Parkinson\u2019s disease with motor fluctuations and dyskinesia","volume":"23","author":"Hauser","year":"2000","journal-title":"Clin Neuropharmacol"},{"key":"10.3233\/JPD-230051_ref28","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1002\/mds.20248","article-title":"Parkinson\u2019s disease home diary: Further validation amd implications for clinical trials","volume":"19","author":"Hauser","year":"2004","journal-title":"Mov Disord"},{"key":"10.3233\/JPD-230051_ref29","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1097\/01.WNF.0000229546.81245.7F","article-title":"Patient evaluation of a home diary to assess duration and severity of dyskinesia in parkinson disease","volume":"29","author":"Hauser","year":"2006","journal-title":"Clin Neuropharmacol"},{"key":"10.3233\/JPD-230051_ref30","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1136\/jnnp.2003.022780","article-title":"Use and interpretation of on\/off diaries in Parkinson\u2019s disease","volume":"75","author":"Reimer","year":"2004","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.3233\/JPD-230051_ref31","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1097\/01.WNF.0000232277.68501.08","article-title":"End-of-dose wearing off in parkinson disease: A 9-question survey assessment","volume":"29","author":"Stacy","year":"2006","journal-title":"Clin Neuropharmacol"},{"key":"10.3233\/JPD-230051_ref32","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s00702-006-0554-y","article-title":"Development of a patient questionnaire to facilitate recognition of motor and non-motor wearing-off in Parkinson\u2019s disease","volume":"114","author":"Stacy","year":"2007","journal-title":"J Neural Transm"},{"key":"10.3233\/JPD-230051_ref33","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1002\/mds.20844","article-title":"International multicenter pilot study of the first comprehensive self-completed nonmotor symptoms questionnaire for Parkinson\u2019s disease: The NMSQuest study","volume":"21","author":"Chaudhuri","year":"2006","journal-title":"Mov Disord"},{"key":"10.3233\/JPD-230051_ref34","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1002\/mds.21596","article-title":"The metric properties of a novel non-motor symptoms scale for Parkinson\u2019s disease: Results from an international pilot study","volume":"22","author":"Chaudhuri","year":"2007","journal-title":"Mov Disord"},{"key":"10.3233\/JPD-230051_ref35","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1002\/mdc3.12728","article-title":"Pilot study of the international Parkinson and Movement Disorder Society-sponsored Non-motor Rating Scale (MDS-NMS)","volume":"6","author":"Martinez-Martin","year":"2019","journal-title":"Mov Disord Clin Pract"},{"key":"10.3233\/JPD-230051_ref36","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1176\/jnp.4.2.134","article-title":"Reliability, validity, and clinical correlates of apathy in Parkinson\u2019s disease","volume":"4","author":"Starkstein","year":"1992","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"10.3233\/JPD-230051_ref37","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/0165-1781(91)90040-V","article-title":"Reliability and validity of the Apathy Evaluation Scale","volume":"38","author":"Marin","year":"1991","journal-title":"Psychiatry Res"},{"key":"10.3233\/JPD-230051_ref38","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1136\/jnnp.2005.075929","article-title":"The Lille apathy rating scale (LARS), a new instrument for detecting and quantifying apathy: Validation in Parkinson\u2019s disease","volume":"77","author":"Sockeel","year":"2006","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.3233\/JPD-230051_ref39","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/0022-3956(82)90033-4","article-title":"Development and validation of a geriatric depression screening scale: A preliminary report","volume":"17","author":"Yesavage","year":"1982","journal-title":"J Psychiatr Res"},{"key":"10.3233\/JPD-230051_ref40","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1136\/jnnp.2004.057984","article-title":"Reliability and validity of the Geriatric Depression Scale in depression in Parkinson\u2019s disease","volume":"76","author":"Ertan","year":"2005","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.3233\/JPD-230051_ref41","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1002\/mds.21023","article-title":"Validity of the 30-item geriatric depression scale in patients with Parkinson\u2019s disease","volume":"21","author":"McDonald","year":"2006","journal-title":"Mov Disord"},{"key":"10.3233\/JPD-230051_ref42","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1046\/j.1525-1497.2001.016009606.x","article-title":"The PHQ-9: Validity of a brief depression severity measure","volume":"16","author":"Kroenke","year":"2001","journal-title":"J Gen Intern Med"},{"key":"10.3233\/JPD-230051_ref44","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1176\/appi.ajp.2011.10111704","article-title":"The Columbia-suicide severity rating scale: Initial validity and internal consistency findings from three multisite studies with adolescents and adults","volume":"168","author":"Posner","year":"2011","journal-title":"Am J Psychiatry"},{"key":"10.3233\/JPD-230051_ref45","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1001\/archneur.1989.00520460115022","article-title":"The fatigue severity scale: Application to patients with multiple sclerosis and systemic lupus erythematosus","volume":"46","author":"Krupp","year":"1989","journal-title":"Arch Neurol"},{"key":"10.3233\/JPD-230051_ref46","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1002\/mds.26270","article-title":"King\u2019s Parkinson\u2019s disease pain scale, the first scale for pain in PD: An international validation","volume":"30","author":"Chaudhuri","year":"2015","journal-title":"Mov Disord"},{"key":"10.3233\/JPD-230051_ref47","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1002\/mds.22575","article-title":"Performance of the Scale for Assessment of Positive Symptoms in Parkinson\u2019s disease psychosis","volume":"25","author":"Voss","year":"2010","journal-title":"Mov Disord"},{"key":"10.3233\/JPD-230051_ref48","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.parkreldis.2018.04.008","article-title":"Comprehensive identification of delusions and olfactory, tactile, gustatory, and minor hallucinations in Parkinson\u2019s disease psychosis","volume":"54","author":"Kulick","year":"2018","journal-title":"Parkinsonism Relat Disord"},{"key":"10.3233\/JPD-230051_ref49","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1093\/sleep\/14.6.540","article-title":"A new method for measuring daytime sleepiness: The Epworth sleepiness scale","volume":"14","author":"Johns","year":"1991","journal-title":"Sleep"},{"key":"10.3233\/JPD-230051_ref50","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1002\/mds.23476","article-title":"Parkinson\u2019s disease sleep scale-validation of the revised version PDSS-2","volume":"26","author":"Trenkwalder","year":"2011","journal-title":"Mov Disord"},{"key":"10.3233\/JPD-230051_ref51","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1002\/mds.20153","article-title":"Assessment of autonomic dysfunction in Parkinson\u2019s disease: The SCOPA-AUT","volume":"19","author":"Visser","year":"2004","journal-title":"Mov Disord"},{"key":"10.3233\/JPD-230051_ref52","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1111\/j.1532-5415.2005.53221.x","article-title":"The Montreal Cognitive Assessment, MoCA: A brief screening tool for mild cognitive impairment","volume":"53","author":"Nasreddine","year":"2005","journal-title":"J Am Geriatr Soc"},{"key":"10.3233\/JPD-230051_ref53","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1002\/mds.22017","article-title":"The Montreal Cognitive Assessment as a screening tool for cognitive impairment in Parkinson\u2019s disease","volume":"23","author":"Gill","year":"2008","journal-title":"Mov Disord"},{"key":"10.3233\/JPD-230051_ref54","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1212\/WNL.0b013e3181c34b47","article-title":"Validity of the MoCA and MMSE in the detection of MCI and dementia in Parkinson disease","volume":"73","author":"Hoops","year":"2009","journal-title":"Neurology"},{"key":"10.3233\/JPD-230051_ref55","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1212\/WNL.0b013e3181fc29c9","article-title":"The MoCA: Well-suited screen for cognitive impairment in parkinson disease","volume":"75","author":"Dalrymple-Alford","year":"2010","journal-title":"Neurology"},{"key":"10.3233\/JPD-230051_ref56","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1177\/0891988712445086","article-title":"Clinical validity of the Mattis dementia rating scale-2 in Parkinson disease with MCI and dementia","volume":"25","author":"Matteau","year":"2012","journal-title":"J Geriatr Psychiatry Neurol"},{"key":"10.3233\/JPD-230051_ref57","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1002\/mds.22007","article-title":"Parkinson\u2019s disease-cognitive rating scale: A new cognitive scale specific for Parkinson\u2019s disease","volume":"23","author":"Pagonabarraga","year":"2008","journal-title":"Mov Disord"},{"key":"10.3233\/JPD-230051_ref58","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1002\/mds.25568","article-title":"Parkinson\u2019s disease-cognitive rating scale: Psychometrics for mild cognitive impairment","volume":"28","author":"Fern\u00e1ndez de Bobadilla","year":"2013","journal-title":"Mov Disord"},{"key":"10.3233\/JPD-230051_ref59","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/mdc3.12338","article-title":"Validation of the Parkinson\u2019s Disease-Cognitive Rating Scale applying the Movement Disorder Society Task Force Criteria for Dementia associated with Parkinson\u2019s disease","volume":"4","author":"Serrano-Due\u00f1as","year":"2017","journal-title":"Mov Disord Clin Pract"},{"key":"10.3233\/JPD-230051_ref60","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1002\/gps.1610","article-title":"The Addenbrooke\u2019s Cognitive Examination revised (ACE-R): A brief cognitive test battery for dementia screening","volume":"21","author":"Mioshi","year":"2006","journal-title":"Int J Geriatr Psychiatry"},{"key":"10.3233\/JPD-230051_ref61","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/j.1468-1331.2008.02384.x","article-title":"Addenbrooke\u2019s Cognitive Examination validation in Parkinson\u2019s disease","volume":"16","author":"Reyes","year":"2009","journal-title":"Eur J Neurol"},{"key":"10.3233\/JPD-230051_ref62","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1002\/mds.25084","article-title":"Addenbrooke\u2019s Cognitive Examination-revised for mild cognitive impairment in Parkinson\u2019s disease","volume":"27","author":"McColgan","year":"2012","journal-title":"Mov Disord"},{"key":"10.3233\/JPD-230051_ref63","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1136\/jnnp-2012-303618","article-title":"The Addenbrooke\u2019s Cognitive Examination for the differential diagnosis and longitudinal assessment of patients with parkinsonian disorders","volume":"84","author":"Rittman","year":"2013","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.3233\/JPD-230051_ref64","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1176\/ajp.141.11.1356","article-title":"A new rating scale for Alzheimer\u2019s disease","volume":"141","author":"Rosen","year":"1984","journal-title":"Am J Psychiatry"},{"key":"10.3233\/JPD-230051_ref65","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","article-title":"\u201cMini-mental state\u201d. A practical method for grading the cognitive state of patients for the clinician","volume":"12","author":"Folstein","year":"1975","journal-title":"J Psychiatr Res"},{"key":"10.3233\/JPD-230051_ref66","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1155\/1995\/304876","article-title":"Mini-Mental Parkinson: First validation study of a new bedside test constructed for Parkinson\u2019s disease","volume":"8","author":"Mahieux","year":"1995","journal-title":"Behav Neurol"},{"key":"10.3233\/JPD-230051_ref67","doi-asserted-by":"crossref","first-page":"2555","DOI":"10.1002\/mds.23322","article-title":"Metric properties of the mini-mental Parkinson and SCOPA-COG scales for rating cognitive deterioration in Parkinson\u2019s disease","volume":"25","author":"Serrano-Due\u00f1as","year":"2010","journal-title":"Mov Disord"},{"key":"10.3233\/JPD-230051_ref68","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1212\/01.WNL.0000091864.39702.1C","article-title":"Assessment of cognition in Parkinson\u2019s disease","volume":"61","author":"Marinus","year":"2003","journal-title":"Neurology"},{"key":"10.3233\/JPD-230051_ref69","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/s41531-022-00320-z","article-title":"Parkinson\u2019s disease clinical milestones and mortality","volume":"8","author":"Gonzalez","year":"2022","journal-title":"NPJ Parkinsons Dis"},{"key":"10.3233\/JPD-230051_ref70","first-page":"152","article-title":"Projection technique for evaluating surgery in Parkinson\u2019s disease","volume":"232","author":"Schwab","year":"1969","journal-title":"Third Symposium on Parkinson\u2019s Diseases Disease"},{"key":"10.3233\/JPD-230051_ref71","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1002\/1531-8257(200003)15:2<335::AID-MDS1022>3.0.CO;2-V","article-title":"Schwab & England- standardization of administration","volume":"15","author":"McRae","year":"2000","journal-title":"Mov Disord"},{"key":"10.3233\/JPD-230051_ref72","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/BF02596437","article-title":"The functional status questionnaire: Reliability and validity when used in primary care","volume":"1","author":"Jette","year":"1986","journal-title":"J Gen Intern Med"},{"key":"10.3233\/JPD-230051_ref73","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1023\/A:1008838317063","article-title":"The usefulness of the Functional Status Questionnaire and Medical Outcomes Study Short Form in Parkinson\u2019s disease research","volume":"7","author":"Rubenstein","year":"1998","journal-title":"Qual Life Res"},{"key":"10.3233\/JPD-230051_ref74","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/mds.21198","article-title":"Movement disorder society-sponsored revision of the unified Parkinson\u2019s disease rating scale (MDS-UPDRS): Process, format, and clinimetric testing plan","volume":"22","author":"Goetz","year":"2007","journal-title":"Mov Disord"},{"key":"10.3233\/JPD-230051_ref75","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s11136-011-9927-2","article-title":"Development of a self-report measure of capability wellbeing for adults: The ICECAP-A","volume":"21","author":"Al-Janabi","year":"2012","journal-title":"Qual Life Res"},{"key":"10.3233\/JPD-230051_ref76","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/j.socscimed.2008.05.015","article-title":"Valuing the ICECAP capability index for older people","volume":"67","author":"Coast","year":"2008","journal-title":"Soc Sci Med"},{"key":"10.3233\/JPD-230051_ref77","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s11136-015-1071-y","article-title":"Development and validation of a carers quality-of-life questionnaire for parkinsonism (PQoL Carers)","volume":"25","author":"Pillas","year":"2016","journal-title":"Qual Life Res"},{"key":"10.3233\/JPD-230051_ref78","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.parkreldis.2012.01.007","article-title":"The development and validation of a quality of life measure for the carers of people with Parkinson\u2019s disease (the PDQ-Carer)","volume":"18","author":"Jenkinson","year":"2012","journal-title":"Parkinsonism Relat Disord"},{"key":"10.3233\/JPD-230051_ref79","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1093\/geront\/20.6.649","article-title":"Relatives of the impaired elderly: Correlates of feelings of burden","volume":"20","author":"Zarit","year":"1980","journal-title":"Gerontologist"},{"key":"10.3233\/JPD-230051_ref80","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1002\/mds.10438","article-title":"Health status measurement in Parkinson\u2019s disease: Validity of the PDQ-39 and Nottingham Health Profile","volume":"18","author":"Hagell","year":"2003","journal-title":"Mov Disord"},{"key":"10.3233\/JPD-230051_ref81","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0168-8510(90)90421-9","article-title":"EuroQol - a new facility for the measurement of health-related quality of life","volume":"16","author":"The EuroQoL Group","year":"1990","journal-title":"Health Policy"},{"key":"10.3233\/JPD-230051_ref82","unstructured":"EuroQol Research Foundation (2019) EQ-5D-5L User Guide v3.0, Computer, Long Beach, CA, pp. 169\u2013232."},{"key":"10.3233\/JPD-230051_ref83","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","article-title":"The MOS 36-item short-form health survey (Sf-36): I. conceptual framework and item selection","volume":"30","author":"Ware","year":"1992","journal-title":"Med Care"},{"key":"10.3233\/JPD-230051_ref84","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1007\/s11136-009-9530-y","article-title":"SF-36 includes less Parkinson Disease (PD)-targeted content but is more responsive to change than two PD-targeted health-related quality of life measures","volume":"18","author":"Brown","year":"2009","journal-title":"Qual Life Res"},{"key":"10.3233\/JPD-230051_ref85","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1097\/00005650-199603000-00003","article-title":"A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity","volume":"34","author":"Ware","year":"1996","journal-title":"Med Care"},{"key":"10.3233\/JPD-230051_ref86","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1097\/01.mlr.0000135827.18610.0d","article-title":"The estimation of a preference-based index from the SF-12","volume":"42","author":"Brazier","year":"2004","journal-title":"Med Care"},{"key":"10.3233\/JPD-230051_ref87","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s11136-011-9958-8","article-title":"Neuro-QOL: Quality of life item banks for adults with neurological disorders: Item development and calibrations based upon clinical and general population testing","volume":"21","author":"Gershon","year":"2012","journal-title":"Qual Life Res"},{"key":"10.3233\/JPD-230051_ref88","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jclinepi.2006.06.025","article-title":"Evaluation of a preliminary physical function item bank supported the expected advantages of the Patient-Reported Outcomes Measurement Information System (PROMIS)","volume":"61","author":"Rose","year":"2008","journal-title":"J Clin Epidemiol"},{"key":"10.3233\/JPD-230051_ref89","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1002\/mds.26546","article-title":"Neuro-QoL health-related quality of life measurement system: Validation in Parkinson\u2019s disease","volume":"31","author":"Nowinski","year":"2016","journal-title":"Mov Disord"},{"key":"10.3233\/JPD-230051_ref90","doi-asserted-by":"crossref","first-page":"129","DOI":"10.3928\/19404921-20180329-01","article-title":"Feasibility of using PROMIS\u00ae in individuals with advanced Parkinson\u2019s disease and their caregivers","volume":"11","author":"Shin","year":"2018","journal-title":"Res Gerontol Nurs"},{"key":"10.3233\/JPD-230051_ref91","doi-asserted-by":"crossref","first-page":"375","DOI":"10.3109\/07853890109002092","article-title":"The Health Utilities Index (HUI\u00ae) system for assessing health-related quality of life in clinical studies","volume":"33","author":"Furlong","year":"2001","journal-title":"Ann Med"},{"key":"10.3233\/JPD-230051_ref92","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/1477-7525-1-54","article-title":"The Health Utilities Index (HUI\u00ae): Concepts, measurement properties and applications","volume":"13","author":"Horsman","year":"2003","journal-title":"Health Qual Life Outcomes"},{"key":"10.3233\/JPD-230051_ref93","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/BF02260863","article-title":"The development and validation of a short measure of functioning and well being for individuals with Parkinson\u2019s disease","volume":"4","author":"Peto","year":"1995","journal-title":"Qual Life Res"},{"key":"10.3233\/JPD-230051_ref94","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1080\/08870449708406741","article-title":"The PDQ-8: Development and validation of a short-form Parkinson\u2019s disease questionnaire","volume":"12","author":"Jenkinson","year":"1997","journal-title":"Psychol Health"},{"key":"10.3233\/JPD-230051_ref95","first-page":"200","article-title":"Costing psychiatric interventions","author":"Beecham","year":"2001","journal-title":"Measuring Mental Health Needs"},{"key":"10.3233\/JPD-230051_ref96","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jpainsymman.2009.04.006","article-title":"Capturing the costs of end-of-life care: Comparisons of multiple sclerosis, Parkinson\u2019s disease, and dementia","volume":"38","author":"McCrone","year":"2009","journal-title":"J Pain Symptom Manage"},{"key":"10.3233\/JPD-230051_ref97","unstructured":"Personal Social Services Research Unit. Client Service Receipt Inventory (CSRI), https:\/\/www.pssru.ac.uk\/csri\/client-service-receipt-inventory\/."},{"key":"10.3233\/JPD-230051_ref98","doi-asserted-by":"crossref","first-page":"E1528","DOI":"10.1212\/WNL.0000000000006366","article-title":"Smartphone motor testing to distinguish idiopathic REM sleep behavior disorder, controls, and PD","volume":"91","author":"Arora","year":"2018","journal-title":"Neurology"},{"key":"10.3233\/JPD-230051_ref99","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/s41531-020-00135-w","article-title":"The CloudUPDRS smartphone software in Parkinson\u2019s study: Cross-validation against blinded human raters","volume":"6","author":"Jha","year":"2020","journal-title":"NPJ Parkinsons Dis"},{"key":"10.3233\/JPD-230051_ref100","doi-asserted-by":"crossref","first-page":"3320","DOI":"10.3390\/s19153320","article-title":"How to select balance measures sensitive to parkinson\u2019s disease from body-worn inertial sensors\u2014 separating the trees from the forest","volume":"19","author":"Hasegawa","year":"2019","journal-title":"Sensors (Switzerland)"},{"key":"10.3233\/JPD-230051_ref101","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1007\/s00415-020-09696-5","article-title":"Quantity and quality of gait and turning in people with multiple sclerosis, Parkinson\u2019s disease and matched controls during daily living","volume":"267","author":"Shah","year":"2020","journal-title":"J Neurol"},{"key":"10.3233\/JPD-230051_ref102","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1001\/jamaneurol.2018.0809","article-title":"Using smartphones and machine learning to quantify Parkinson disease severity the mobile Parkinson disease score","volume":"75","author":"Zhan","year":"2018","journal-title":"JAMA Neurol"},{"key":"10.3233\/JPD-230051_ref103","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3233\/JPD-2012-11071","article-title":"Automated assessment of bradykinesia and dyskinesia in Parkinson\u2019s disease","volume":"2","author":"Griffiths","year":"2012","journal-title":"J Parkinsons Dis"},{"key":"10.3233\/JPD-230051_ref104","doi-asserted-by":"crossref","first-page":"eabd7865","DOI":"10.1126\/scitranslmed.abd7865","article-title":"Smartwatch inertial sensors continuously monitor real-world motor fluctuations in Parkinson\u2019s disease","volume":"13","author":"Powers","year":"2021","journal-title":"Sci Transl Med"},{"key":"10.3233\/JPD-230051_ref105","doi-asserted-by":"crossref","first-page":"6992","DOI":"10.3390\/s20236992","article-title":"Gait analysis with wearables can accurately classify fallers from non-fallers: A step toward better management of neurological disorders","volume":"20","author":"Rehman","year":"2020","journal-title":"Sensors (Basel)"},{"key":"10.3233\/JPD-230051_ref106","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/s41746-021-00513-5","article-title":"Walking on common ground: A cross-disciplinary scoping review on the clinical utility of digital mobility outcomes","volume":"4","author":"Polhemus","year":"2021","journal-title":"NPJ Digit Med"},{"key":"10.3233\/JPD-230051_ref107","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.3233\/JPD-202471","article-title":"Body-worn sensors for remote monitoring of Parkinson\u2019s disease motor symptoms: Vision, state of the art, and challenges ahead","volume":"11","author":"Del","year":"2021","journal-title":"J Parkinsons Dis"},{"key":"10.3233\/JPD-230051_ref108","doi-asserted-by":"crossref","first-page":"705407","DOI":"10.3389\/fneur.2021.705407","article-title":"A Phase II Study to Evaluate the Safety and Efficacy of Prasinezumab in Early Parkinson\u2019s Disease (PASADENA): Rationale, design, and baseline data","volume":"12","author":"Pagano","year":"2021","journal-title":"Front Neurol"},{"issue":"15 Supp","key":"10.3233\/JPD-230051_ref109","doi-asserted-by":"crossref","first-page":"4.7-005","DOI":"10.1212\/WNL.92.15_supplement.P4.7-005","article-title":"Preliminary validation of a novel, comprehensive digital biomarker smartphone application to assess motor symptoms in recently diagnosed Parkinson patients","volume":"92","author":"Lipsmeier","year":"2019","journal-title":"Neurology"},{"key":"10.3233\/JPD-230051_ref110","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/j.1532-5415.1991.tb01616.x","article-title":"The timed \u201cUp & Go\u201d: A test of basic functional mobility for frail elderly persons","volume":"39","author":"Podsiadlo","year":"1991","journal-title":"J Am Geriatr Soc"},{"key":"10.3233\/JPD-230051_ref111","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1037\/h0061266","article-title":"The Purdue Pegboard: Norms and studies of reliability and validity","volume":"32","author":"Tiffin","year":"1948","journal-title":"J Appl Psychol"},{"key":"10.3233\/JPD-230051_ref112","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.physio.2019.12.002","article-title":"Construct validity of the 9-Hole Peg Test and Purdue Pegboard Test in people with mild to moderately severe Parkinson\u2019s disease","volume":"107","author":"Proud","year":"2020","journal-title":"Physiotherapy"},{"key":"10.3233\/JPD-230051_ref113","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1212\/WNL.10.12.1096","article-title":"A preliminary report on the measurement of parkinson\u2019s disease","volume":"10","author":"Burns","year":"1960","journal-title":"Neurology"},{"key":"10.3233\/JPD-230051_ref114","doi-asserted-by":"crossref","first-page":"e96260","DOI":"10.1371\/journal.pone.0096260","article-title":"Bradykinesia-akinesia incoordination test: Validating an online keyboard test of upper limb function","volume":"9","author":"Noyce","year":"2014","journal-title":"PLoS One"},{"key":"10.3233\/JPD-230051_ref115","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1002\/mdc3.12798","article-title":"The BRadykinesia Akinesia INcoordination (BRAIN) Tap Test: Capturing the sequence effect","volume":"6","author":"Hasan","year":"2019","journal-title":"Mov Disord Clin Pract"},{"key":"10.3233\/JPD-230051_ref116","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1177\/153944928500500102","article-title":"Adult norms for the nine-hole peg test of finger dexterity","volume":"5","author":"Mathiowetz","year":"1985","journal-title":"Occup Ther J Res"},{"key":"10.3233\/JPD-230051_ref117","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1097\/NPT.0b013e318235da08","article-title":"The 9-hole peg test of upper extremity function: Average values, test-retest reliability, and factors contributing to performance in people with Parkinson disease","volume":"35","author":"Earhart","year":"2011","journal-title":"J Neurol Phys Ther"},{"key":"10.3233\/JPD-230051_ref118","doi-asserted-by":"crossref","first-page":"3834","DOI":"10.1080\/09638288.2020.1754474","article-title":"Hand dexterity assessment in Parkinson\u2019s disease: Construct validity of the 9-Hole peg test for the more affected hand","volume":"43","author":"Proud","year":"2021","journal-title":"Disabil Rehabil"},{"key":"10.3233\/JPD-230051_ref119","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1136\/jnnp-2021-327880","article-title":"A composite clinical motor score as a comprehensive and sensitive outcome measure for Parkinson\u2019s disease","volume":"93","author":"Lo","year":"2022","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.3233\/JPD-230051_ref120","doi-asserted-by":"crossref","first-page":"572976","DOI":"10.3389\/fneur.2020.572976","article-title":"Neuroimaging advances in Parkinson\u2019s disease and atypical Parkinsonian syndromes","volume":"11","author":"Saeed","year":"2020","journal-title":"Front Neurol"},{"key":"10.3233\/JPD-230051_ref121","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/jnc.15561","article-title":"Dopaminergic imaging in degenerative parkinsonisms, an established clinical diagnostic tool","volume":"164","author":"Nicastro","year":"2021","journal-title":"J Neurochem"},{"key":"10.3233\/JPD-230051_ref122","doi-asserted-by":"crossref","first-page":"412486","DOI":"10.1155\/2012\/412486","article-title":"SPECT molecular imaging in Parkinson\u2019s disease","volume":"2012","author":"Wang","year":"2012","journal-title":"J Biomed Biotechnol"},{"key":"10.3233\/JPD-230051_ref123","doi-asserted-by":"crossref","first-page":"11234","DOI":"10.3390\/ijms222011234","article-title":"Dopamine transporter imaging, current status of a potential biomarker: A comprehensive review","volume":"22","author":"Palermo","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.3233\/JPD-230051_ref124","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.parkreldis.2020.08.010","article-title":"Multimodal dopamine transporter (DAT) imaging and magnetic resonance imaging (MRI) to characterise early Parkinson\u2019s disease","volume":"79","author":"Porter","year":"2020","journal-title":"Parkinsonism Relat Disord"},{"key":"10.3233\/JPD-230051_ref125","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1002\/mds.27361","article-title":"Longitudinal change of clinical and biological measures in early Parkinson\u2019s disease: Parkinson\u2019s Progression Markers Initiative Cohort","volume":"33","author":"Simuni","year":"2018","journal-title":"Mov Disord"},{"key":"10.3233\/JPD-230051_ref126","first-page":"1","article-title":"Imaging of dopamine transporters with iodine-123-\u03b2-CIT and SPECT in Parkinson\u2019s disease","volume":"38","author":"Asenbaum","year":"1997","journal-title":"J Nucl Med"},{"key":"10.3233\/JPD-230051_ref127","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/0969-8051(95)02020-9","article-title":"Evaluation of [123I]\u03b2-CIT binding with SPECT in controls, early and late Parkinson\u2019s disease","volume":"22","author":"Vermeulen","year":"1995","journal-title":"Nucl Med Biol"},{"key":"10.3233\/JPD-230051_ref128","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1002\/mds.870120107","article-title":"Long-term changes of striatal dopamine D2 receptors in patients with Parkinson\u2019s disease: A study with positron emission tomography and [11C]raclopride","volume":"12","author":"Antonini","year":"1997","journal-title":"Mov Disord"},{"key":"10.3233\/JPD-230051_ref129","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1002\/mds.10042","article-title":"Combination of dopamine transporter and D2 receptor SPECT in the diagnostic evaluation of PD, MSA, and PSP","volume":"17","author":"Kim","year":"2002","journal-title":"Mov Disord"},{"key":"10.3233\/JPD-230051_ref130","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1002\/ana.410340304","article-title":"Human positron emission tomographic [18F]Fluorodopa studies correlate with dopamine cell counts and levels","volume":"34","author":"Snow","year":"1993","journal-title":"Ann Neurol"},{"key":"10.3233\/JPD-230051_ref131","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1002\/mds.27183","article-title":"11 C-PE2I and 18 F-Dopa PET for assessing progression rate in Parkinson\u2019s: A longitudinal study","volume":"33","author":"Li","year":"2018","journal-title":"Mov Disord"},{"key":"10.3233\/JPD-230051_ref132","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.parkreldis.2015.11.029","article-title":"Neuroimaging and clinical predictors of fatigue in Parkinson disease","volume":"23","author":"Chou","year":"2016","journal-title":"Parkinsonism Relat Disord"},{"key":"10.3233\/JPD-230051_ref133","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1002\/mds.22484","article-title":"A follow-up study on 6-[18F]Fluoro-L-dopa uptake in early Parkinson\u2019s disease shows nonlinear progressionin the putamen","volume":"24","author":"Br\u00fcck","year":"2009","journal-title":"Mov Disord"},{"key":"10.3233\/JPD-230051_ref134","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1007\/s00259-009-1266-y","article-title":"EANM procedure guideline for brain perfusion SPECT using 99mTc-labelled radiopharmaceuticals, version 2","volume":"36","author":"Kapucu","year":"2009","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.3233\/JPD-230051_ref135","doi-asserted-by":"crossref","first-page":"851609","DOI":"10.3389\/fneur.2022.851609","article-title":"The Legacy of the TTASAAN Report \u2013 premature conclusions and forgotten promises about SPECT neuroimaging: A review of policy and practice part II","volume":"13","author":"Pavel","year":"2022","journal-title":"Front Neurol"},{"key":"10.3233\/JPD-230051_ref136","doi-asserted-by":"crossref","first-page":"749579","DOI":"10.3389\/fneur.2021.749579","article-title":"The Legacy of the TTASAAN Report\u2014 premature conclusions and forgotten promises: A review of policy and practice part I","volume":"12","author":"Pavel","year":"2022","journal-title":"Front Neurol"},{"key":"10.3233\/JPD-230051_ref137","first-page":"446","article-title":"Parkinson\u2019s disease dementia: Clinical correlates of brain SPECT perfusion and treatment","volume":"22","author":"Kramberger","year":"2010","journal-title":"Psychiatr Danub"},{"key":"10.3233\/JPD-230051_ref138","doi-asserted-by":"crossref","first-page":"673","DOI":"10.21037\/apm-21-3916","article-title":"Systematic review and meta-analysis of diagnostic test accuracy (DTA) studies: The role of cerebral perfusion imaging in prognosis evaluation of mild cognitive impairment","volume":"11","author":"Zhu","year":"2022","journal-title":"Ann Palliat Med"},{"key":"10.3233\/JPD-230051_ref139","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1002\/mds.10270","article-title":"Tc-99m ethylene cysteinate dimer SPECT in the differential diagnosis of parkinsonism","volume":"17","author":"Feigin","year":"2002","journal-title":"Mov Disord"},{"key":"10.3233\/JPD-230051_ref140","doi-asserted-by":"crossref","first-page":"191","DOI":"10.2967\/jnmt.109.067850","article-title":"Procedure guideline for brain perfusion SPECT using 99mTc radiopharmaceuticals 3.0","volume":"37","author":"Juni","year":"2009","journal-title":"J Nucl Med Technol"},{"key":"10.3233\/JPD-230051_ref141","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1002\/ana.25236","article-title":"Serotonin, \u03b2-amyloid, and cognition in Parkinson disease","volume":"83","author":"Kotagal","year":"2018","journal-title":"Ann Neurol"},{"key":"10.3233\/JPD-230051_ref142","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1002\/mds.28360","article-title":"Cholinergic denervation patterns across cognitive domains in Parkinson\u2019s disease","volume":"36","author":"van der Zee","year":"2021","journal-title":"Mov Disord"},{"key":"10.3233\/JPD-230051_ref143","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1186\/s12883-020-01811-3","article-title":"Study protocol of the DUtch PARkinson Cohort (DUPARC): A prospective, observational study of de novo Parkinson\u2019s disease patients for the identification and validation of biomarkers for Parkinson\u2019s disease subtypes, progression and pathophysiology","volume":"20","author":"Boertien","year":"2020","journal-title":"BMC Neurol"},{"key":"10.3233\/JPD-230051_ref144","doi-asserted-by":"crossref","first-page":"391","DOI":"10.3389\/fneur.2019.00391","article-title":"Beta amyloid deposition is not associated with cognitive impairment in Parkinson\u2019s disease","volume":"10","author":"Melzer","year":"2019","journal-title":"Front Neurol"},{"key":"10.3233\/JPD-230051_ref145","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1016\/j.jalz.2015.02.004","article-title":"Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer\u2019s disease: Phase 3 study","volume":"11","author":"Sabri","year":"2015","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JPD-230051_ref146","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1159\/000464322","article-title":"Extremely low prevalence of amyloid positron emission tomography positivity in Parkinson\u2019s disease without dementia","volume":"77","author":"Mashima","year":"2017","journal-title":"Eur Neurol"},{"key":"10.3233\/JPD-230051_ref147","doi-asserted-by":"crossref","first-page":"380","DOI":"10.3390\/metabo10100380","article-title":"The impact of amyloid-beta positivity with 18F-Florbetaben PET on neuropsychological aspects in Parkinson\u2019s disease dementia","volume":"10","author":"Na","year":"2020","journal-title":"Metabolites"},{"key":"10.3233\/JPD-230051_ref148","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1002\/mds.29220","article-title":"Serotonin transporter imaging in multiple system atrophy and Parkinson\u2019s disease","volume":"37","author":"Chou","year":"2022","journal-title":"Mov Disord"},{"key":"10.3233\/JPD-230051_ref149","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1007\/s00259-020-04683-4","article-title":"High-resolution PET imaging reveals subtle impairment of the serotonin transporter in an early non-depressed Parkinson\u2019s disease cohort","volume":"47","author":"Fazio","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.3233\/JPD-230051_ref150","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1159\/000441421","article-title":"PET radioligands reveal the basis of dementia in Parkinson\u2019s disease and dementia with Lewy bodies","volume":"2016","author":"Gomperts","year":"2016","journal-title":"Neurodegener Dis"},{"key":"10.3233\/JPD-230051_ref151","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1007\/s00415-022-11342-1","article-title":"Adenosine A2A receptor availability in patients with early- and moderate-stage Parkinson\u2019s disease","volume":"270","author":"Waggan","year":"2022","journal-title":"J Neurol"},{"key":"10.3233\/JPD-230051_ref152","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.neuropharm.2018.09.036","article-title":"Occupancy of adenosine A2A receptors by istradefylline in patients with Parkinson\u2019s disease using 11C-preladenant PET","volume":"143","author":"Ishibashi","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.3233\/JPD-230051_ref153","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1007\/s00259-021-05603-w","article-title":"EANM procedure guidelines for brain PET imaging using [18F]FDG, version 3","volume":"49","author":"Guedj","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.3233\/JPD-230051_ref154","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.parkreldis.2021.03.030","article-title":"Effect of dopaminergic medication on adenosine 2A receptor availability in patients with Parkinson\u2019s disease","volume":"86","author":"Waggan","year":"2021","journal-title":"Parkinsonism Relat Disord"},{"key":"10.3233\/JPD-230051_ref155","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.2967\/jnumed.116.174615","article-title":"SNMMI Procedure Standard \/ EANM Practice Guideline for amyloid PET imaging of the brain 1.0","volume":"57","author":"Minoshima","year":"2016","journal-title":"J Nucl Med"},{"key":"10.3233\/JPD-230051_ref156","doi-asserted-by":"crossref","first-page":"519816","DOI":"10.1155\/2014\/519816","article-title":"Magnetic resonance spectroscopy: An molecular imaging biomarker for Parkinson\u2019s disease?","volume":"2014","author":"Ciurleo","year":"2014","journal-title":"Biomed Res Int"},{"key":"10.3233\/JPD-230051_ref157","doi-asserted-by":"crossref","first-page":"e038911","DOI":"10.1136\/bmjopen-2020-038911","article-title":"Ursodeoxycholic acid as a novel disease-modifying treatment for Parkinson\u2019s disease: Protocol for a two-centre, randomised, double-blind, placebo-controlled trial, the \u201cUP\u201d study","volume":"10","author":"Payne","year":"2020","journal-title":"BMJ Open"},{"key":"10.3233\/JPD-230051_ref158","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.nicl.2017.11.009","article-title":"Patterns of grey matter loss associated with motor subscores in early Parkinson\u2019s disease","volume":"17","author":"Li","year":"2018","journal-title":"Neuroimage Clin"},{"key":"10.3233\/JPD-230051_ref159","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.parkreldis.2013.03.009","article-title":"Combined dementia-risk biomarkers in Parkinson\u2019s disease: A prospective longitudinal study","volume":"19","author":"Compta","year":"2013","journal-title":"Parkinsonism Relat Disord"},{"key":"10.3233\/JPD-230051_ref160","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1002\/mds.25397","article-title":"White matter abnormalities in Parkinson\u2019s disease patients with glucocerebrosidase gene mutations","volume":"28","author":"Agosta","year":"2013","journal-title":"Mov Disord"},{"key":"10.3233\/JPD-230051_ref161","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1093\/brain\/awh088","article-title":"Cerebral atrophy in Parkinson\u2019s disease with and without dementia: A comparison with Alzheimer\u2019s disease, dementia with Lewy bodies and controls","volume":"127","author":"Burton","year":"2004","journal-title":"Brain"},{"key":"10.3233\/JPD-230051_ref162","first-page":"2545","article-title":"Can neuroimaging predict dementia in Parkinson\u2019s disease?","volume":"141","author":"Lanskey","year":"2018","journal-title":"Brain"},{"key":"10.3233\/JPD-230051_ref163","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1007\/s00415-011-5915-2","article-title":"Diffusion tensor imaging and olfactory identification testing in early-stage Parkinson\u2019s disease","volume":"258","author":"Rolheiser","year":"2011","journal-title":"J Neurol"},{"key":"10.3233\/JPD-230051_ref164","doi-asserted-by":"crossref","first-page":"119138","DOI":"10.1016\/j.neuroimage.2022.119138","article-title":"Accuracy and reliability of diffusion imaging models","volume":"254","author":"Seider","year":"2022","journal-title":"Neuroimage"},{"key":"10.3233\/JPD-230051_ref165","doi-asserted-by":"crossref","first-page":"e222","DOI":"10.1016\/S2589-7500(19)30105-0","article-title":"Development and validation of the automated imaging differentiation in parkinsonism (AID-P): A multicentre machine learning study","volume":"1","author":"Archer","year":"2019","journal-title":"Lancet Digit Health"},{"key":"10.3233\/JPD-230051_ref166","doi-asserted-by":"crossref","first-page":"839","DOI":"10.3390\/cells8080839","article-title":"Free-water imaging in white and gray matter in Parkinson\u2019s disease","volume":"8","author":"Andica","year":"2019","journal-title":"Cells"},{"key":"10.3233\/JPD-230051_ref167","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1093\/brain\/awaa216","article-title":"Spatiotemporal changes in substantia nigra neuromelanin content in Parkinson\u2019s disease","volume":"143","author":"Biondetti","year":"2020","journal-title":"Brain"},{"key":"10.3233\/JPD-230051_ref168","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.neulet.2016.09.011","article-title":"A longitudinal study of neuromelanin-sensitive magnetic resonance imaging in Parkinson\u2019s disease","volume":"633","author":"Matsuura","year":"2016","journal-title":"Neurosci Lett"},{"key":"10.3233\/JPD-230051_ref169","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1136\/jnnp-2019-322042","article-title":"Brain iron deposition is linked with cognitive severity in Parkinson\u2019s disease","volume":"91","author":"Thomas","year":"2020","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.3233\/JPD-230051_ref170","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1002\/mds.27717","article-title":"Voxel-based quantitative susceptibility mapping in Parkinson\u2019s disease with mild cognitive impairment","volume":"34","author":"Uchida","year":"2019","journal-title":"Mov Disord"},{"key":"10.3233\/JPD-230051_ref171","doi-asserted-by":"crossref","first-page":"74","DOI":"10.3389\/fneur.2019.00074","article-title":"Brain iron accumulation in atypical parkinsonian syndromes: MRI evidences for distinctive patterns","volume":"10","author":"Lee","year":"2019","journal-title":"Front Neurol"},{"key":"10.3233\/JPD-230051_ref172","doi-asserted-by":"crossref","first-page":"4721","DOI":"10.1007\/s00415-021-10582-x","article-title":"Iron-sensitive magnetic resonance imaging in Parkinson\u2019s disease: A systematic review and meta-analysis","volume":"268","author":"Cho","year":"2021","journal-title":"J Neurol"},{"key":"10.3233\/JPD-230051_ref173","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S1474-4422(19)30024-9","article-title":"CSF and blood biomarkers for Parkinson\u2019s disease","volume":"18","author":"Parnetti","year":"2019","journal-title":"Lancet Neurol"},{"key":"10.3233\/JPD-230051_ref174","doi-asserted-by":"crossref","first-page":"107","DOI":"10.3233\/JPD-202323","article-title":"Neuropathological and biomarker findings in Parkinson\u2019s disease and Alzheimer\u2019s disease: From protein aggregates to synaptic dysfunction","volume":"11","author":"Compta","year":"2021","journal-title":"J Parkinsons Dis"},{"key":"10.3233\/JPD-230051_ref175","doi-asserted-by":"crossref","first-page":"466","DOI":"10.3390\/brainsci10070466","article-title":"Cerebrospinal fluid biomarkers in Parkinson\u2019s disease: A critical overview of the literature and meta-analyses","volume":"10","author":"Katayama","year":"2020","journal-title":"Brain Sci"},{"key":"10.3233\/JPD-230051_ref176","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1007\/s00702-022-02498-1","article-title":"Blood-based biomarker in Parkinson\u2019s disease: Potential for future applications in clinical research and practice","volume":"129","author":"T\u00f6nges","year":"2022","journal-title":"J Neural Transm"},{"key":"10.3233\/JPD-230051_ref177","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1111\/ane.13700","article-title":"Blood based biomarkers for movement disorders","volume":"146","author":"Morris","year":"2022","journal-title":"Acta Neurol Scand"},{"key":"10.3233\/JPD-230051_ref178","doi-asserted-by":"crossref","first-page":"371","DOI":"10.3390\/diagnostics11020371","article-title":"The role of salivary biomarkers in the early diagnosis of Alzheimer\u2019s disease and Parkinson\u2019s disease","volume":"11","author":"Pawlik","year":"2021","journal-title":"Diagnostics"},{"key":"10.3233\/JPD-230051_ref179","doi-asserted-by":"crossref","first-page":"19982","DOI":"10.1038\/s41598-020-77098-8","article-title":"Serum neurofilament light chain withstands delayed freezing and repeated thawing","volume":"10","author":"Altmann","year":"2020","journal-title":"Sci Rep"},{"key":"10.3233\/JPD-230051_ref180","doi-asserted-by":"crossref","first-page":"11034","DOI":"10.1038\/s41598-021-90639-z","article-title":"Seven day pre-analytical stability of serum and plasma neurofilament light chain","volume":"11","author":"Altmann","year":"2021","journal-title":"Sci Rep"},{"key":"10.3233\/JPD-230051_ref181","first-page":"1324","article-title":"Dimethyl fumarate decreases neurofilament light chain in CSF and blood of treatment na\u00efve relapsing MS patients","volume":"90","author":"Sejbaek","year":"2019","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.3233\/JPD-230051_ref182","doi-asserted-by":"crossref","first-page":"3400","DOI":"10.1038\/s41467-021-23620-z","article-title":"A multicentre validation study of the diagnostic value of plasma neurofilament light","volume":"12","author":"Ashton","year":"2021","journal-title":"Nat Commun"},{"key":"10.3233\/JPD-230051_ref183","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1002\/mds.28206","article-title":"Validation of serum neurofilament light chain as a biomarker of Parkinson\u2019s disease progression","volume":"35","author":"Mollenhauer","year":"2020","journal-title":"Mov Disord"},{"key":"10.3233\/JPD-230051_ref184","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1002\/mds.27897","article-title":"CSF or serum neurofilament light added to \u03b1-Synuclein panel discriminates Parkinson\u2019s from controls","volume":"35","author":"Oosterveld","year":"2020","journal-title":"Mov Disord"},{"key":"10.3233\/JPD-230051_ref185","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s12883-022-02558-9","article-title":"Serum NFL discriminates Parkinson disease from essential tremor and reflect motor and cognition severity","volume":"22","author":"Huang","year":"2022","journal-title":"BMC Neurol"},{"key":"10.3233\/JPD-230051_ref186","doi-asserted-by":"crossref","first-page":"571","DOI":"10.3233\/JPD-212866","article-title":"Serum neurofilament light chain as a marker of progression in Parkinson\u2019s disease: Long-term observation and implications of clinical subtypes","volume":"12","author":"Ygland","year":"2021","journal-title":"J Parkinsons Dis"},{"key":"10.3233\/JPD-230051_ref187","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s13024-020-00385-5","article-title":"Utility of plasma Neurofilament light as a diagnostic and prognostic biomarker of the postural instability gait disorder motor subtype in early Parkinson\u2019s disease","volume":"15","author":"Ng","year":"2020","journal-title":"Mol Neurodegener"},{"key":"10.3233\/JPD-230051_ref188","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.parkreldis.2020.04.009","article-title":"Serum neurofilament light chain levels reflect cortical neurodegeneration in de novo Parkinson\u2019s disease","volume":"74","author":"Sampedro","year":"2020","journal-title":"Parkinsonism Relat Disord"},{"key":"10.3233\/JPD-230051_ref189","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1136\/jnnp-2018-320106","article-title":"Neurofilament light chain as a biomarker in neurological disorders","volume":"90","author":"Gaetani","year":"2019","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.3233\/JPD-230051_ref190","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/S1474-4422(20)30071-5","article-title":"Blood phosphorylated tau 181 as a biomarker for Alzheimer\u2019s disease: A diagnostic performance and prediction modelling study using data from four prospective cohorts","volume":"19","author":"Karikari","year":"2020","journal-title":"Lancet Neurol"},{"key":"10.3233\/JPD-230051_ref191","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1001\/jamaneurol.2021.4222","article-title":"Association of plasma p-tau181 and p-tau231 concentrations with cognitive decline in patients with probable dementia with Lewy bodies","volume":"79","author":"Gonzalez","year":"2022","journal-title":"JAMA Neurol"},{"key":"10.3233\/JPD-230051_ref192","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.3233\/JAD-201499","article-title":"An introduction to ultrasensitive assays for plasma tau detection","volume":"80","author":"Ding","year":"2021","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JPD-230051_ref193","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3389\/fnagi.2018.00123","article-title":"Plasma biomarkers differentiate Parkinson\u2019s disease from atypical parkinsonism syndromes","volume":"10","author":"Lin","year":"2018","journal-title":"Front Aging Neurosci"},{"key":"10.3233\/JPD-230051_ref194","doi-asserted-by":"crossref","first-page":"112","DOI":"10.3389\/fnagi.2020.00112","article-title":"Plasma levels of \u03b1-Synuclein, A\u03b2-40 and T-tau as biomarkers to predict cognitive impairment in Parkinson\u2019s disease","volume":"12","author":"Chen","year":"2020","journal-title":"Front Aging Neurosci"},{"key":"10.3233\/JPD-230051_ref195","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1111\/jnc.15601","article-title":"Plasma \u03b1-synuclein and phosphorylated tau 181 as a diagnostic biomarker panel for de novo Parkinson\u2019s disease","volume":"161","author":"Ren","year":"2022","journal-title":"J Neurochem"},{"key":"10.3233\/JPD-230051_ref196","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.3233\/JPD-212694","article-title":"Comparison of different platform immunoassays for the measurement of plasma alpha-synuclein in Parkinson\u2019s disease patients","volume":"11","author":"Youssef","year":"2021","journal-title":"J Parkinsons Dis"},{"key":"10.3233\/JPD-230051_ref197","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1159\/000112832","article-title":"Red blood cells are the major source of alpha-synuclein in blood","volume":"5","author":"Barbour","year":"2008","journal-title":"Neurodegener Dis"},{"key":"10.3233\/JPD-230051_ref198","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.parkreldis.2022.06.001","article-title":"Plasma and serum alpha-synuclein as a biomarker in Parkinson\u2019s disease: A meta-analysis","volume":"99","author":"Zubelzu","year":"2022","journal-title":"Parkinsonism Relat Disord"},{"key":"10.3233\/JPD-230051_ref199","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/ejn.13056","article-title":"Oligomeric \u03b1-synuclein and \u03b2-amyloid variants as potential biomarkers for Parkinson\u2019s and Alzheimer\u2019s diseases","volume":"43","author":"Williams","year":"2016","journal-title":"Eur J Neurosci"},{"key":"10.3233\/JPD-230051_ref200","doi-asserted-by":"crossref","first-page":"623977","DOI":"10.3389\/fnagi.2021.623977","article-title":"Alterations of erythrocytic phosphorylated alpha-synuclein in different subtypes and stages of Parkinson\u2019s disease","volume":"13","author":"Li","year":"2021","journal-title":"Front Aging Neurosci"},{"key":"10.3233\/JPD-230051_ref201","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1111\/ene.14208","article-title":"A longitudinal study on \u03b1-synuclein in plasma neuronal exosomes as a biomarker for Parkinson\u2019s disease development and progression","volume":"27","author":"Niu","year":"2020","journal-title":"Eur J Neurol"},{"key":"10.3233\/JPD-230051_ref202","doi-asserted-by":"crossref","first-page":"3058","DOI":"10.1093\/brain\/awac115","article-title":"Detection of neuron-derived pathological \u03b1-synuclein in blood","volume":"145","author":"Kluge","year":"2022","journal-title":"Brain"},{"key":"10.3233\/JPD-230051_ref203","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1038\/srep02540","article-title":"A longitudinal study on a-synuclein in blood plasma as a biomarker for Parkinson\u2019s disease","volume":"3","author":"Foulds","year":"2013","journal-title":"Sci Rep"},{"key":"10.3233\/JPD-230051_ref204","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.pjnns.2017.11.009","article-title":"The relation between plasma \u03b1-synuclein level and clinical symptoms or signs of Parkinson\u2019s disease","volume":"52","author":"Malec-Litwinowicz","year":"2018","journal-title":"Neurol Neurochir Pol"},{"key":"10.3233\/JPD-230051_ref205","doi-asserted-by":"crossref","first-page":"744","DOI":"10.3390\/biom11050744","article-title":"Plasma extracellular vesicle \u03b1-synuclein level in patients with parkinson\u2019s disease","volume":"11","author":"Chung","year":"2021","journal-title":"Biomolecules"},{"key":"10.3233\/JPD-230051_ref206","doi-asserted-by":"crossref","first-page":"fcac040","DOI":"10.1093\/braincomms\/fcac040","article-title":"Prediction and early biomarkers of cognitive decline in Parkinson disease and atypical parkinsonism: A population-based study","volume":"15","author":"B\u00e4ckstr\u00f6m","year":"2022","journal-title":"Brain Commun"},{"key":"10.3233\/JPD-230051_ref207","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1002\/mds.28056","article-title":"CSF NFL in a longitudinally assessed PD cohort: Age effects and cognitive trajectories","volume":"35","author":"Lerche","year":"2020","journal-title":"Mov Disord"},{"key":"10.3233\/JPD-230051_ref208","doi-asserted-by":"crossref","first-page":"329","DOI":"10.3390\/biom12020329","article-title":"Update on CSF Biomarkers in Parkinson\u2019s disease","volume":"12","author":"Kwon","year":"2022","journal-title":"Biomolecules"},{"key":"10.3233\/JPD-230051_ref209","doi-asserted-by":"crossref","first-page":"e827","DOI":"10.1212\/WNL.0000000000010084","article-title":"NfL as a biomarker for neurodegeneration and survival in Parkinson disease","volume":"95","author":"B\u00e4ckstr\u00f6m","year":"2020","journal-title":"Neurology"},{"key":"10.3233\/JPD-230051_ref210","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1001\/jamaneurol.2015.1449","article-title":"Cerebrospinal fluid patterns and the risk of future dementia in early, incident Parkinson disease","volume":"72","author":"B\u00e4ckstr\u00f6m","year":"2015","journal-title":"JAMA Neurol"},{"key":"10.3233\/JPD-230051_ref211","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.clinbiochem.2019.05.005","article-title":"Elecsys\u00ae total-Tau and Phospho-Tau (181P) CSF assays: Analytical performance of the novel, fully automated immunoassays for quantification of tau proteins in human cerebrospinal fluid","volume":"72","author":"Lifke","year":"2019","journal-title":"Clin Biochem"},{"key":"10.3233\/JPD-230051_ref212","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.parkreldis.2014.12.027","article-title":"CSF tau and tau\/A\u03b242 predict cognitive decline in Parkinson\u2019s disease","volume":"21","author":"Liu","year":"2015","journal-title":"Parkinsonism Relat Disord"},{"key":"10.3233\/JPD-230051_ref213","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1111\/jnc.14569","article-title":"Antibody-based methods for the measurement of \u03b1-synuclein concentration in human cerebrospinal fluid \u2013 method comparison and round robin study","volume":"149","author":"Mollenhauer","year":"2019","journal-title":"J Neurochem"},{"key":"10.3233\/JPD-230051_ref214","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3390\/brainsci11010119","article-title":"Cerebrospinal fluid \u03b1-synuclein species in cognitive and movements disorders","volume":"11","author":"Constantinides","year":"2021","journal-title":"Brain Sci"},{"key":"10.3233\/JPD-230051_ref215","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1002\/mds.26754","article-title":"Longitudinal changes in CSF alpha-synuclein species reflect Parkinson\u2019s disease progression","volume":"31","author":"Majbour","year":"2016","journal-title":"Mov Disord"},{"key":"10.3233\/JPD-230051_ref216","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s40478-021-01175-w","article-title":"Streamlined alpha-synuclein RT-QuIC assay for various biospecimens in Parkinson\u2019s disease and dementia with Lewy bodies","volume":"9","author":"Bargar","year":"2021","journal-title":"Acta Neuropathol Commun"},{"key":"10.3233\/JPD-230051_ref217","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1002\/mds.27646","article-title":"Comparative study of cerebrospinal fluid \u03b1-synuclein seeding aggregation assays for diagnosis of Parkinson\u2019s disease","volume":"34","author":"Kang","year":"2019","journal-title":"Mov Disord"},{"key":"10.3233\/JPD-230051_ref218","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1093\/brain\/awab431","article-title":"Diagnostic value of cerebrospinal fluid alpha-synuclein seed quantification in synucleinopathies","volume":"145","author":"Poggiolini","year":"2021","journal-title":"Brain"},{"key":"10.3233\/JPD-230051_ref219","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1002\/acn3.51280","article-title":"A rapid \u03b1-synuclein seed assay of Parkinson\u2019s disease CSF panel shows high diagnostic accuracy","volume":"8","author":"Orr\u00f9","year":"2021","journal-title":"Ann Clin Transl Neurol"},{"key":"10.3233\/JPD-230051_ref220","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S1474-4422(20)30449-X","article-title":"Detection of \u03b1-synuclein in CSF by RT-QuIC in patients with isolated rapid-eye-movement sleep behaviour disorder: A longitudinal observational study","volume":"20","author":"Iranzo","year":"2021","journal-title":"Lancet Neurol"},{"key":"10.3233\/JPD-230051_ref221","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1001\/jamaneurol.2016.4547","article-title":"Development of a biochemical diagnosis of Parkinson disease by detection of \u03b1-synuclein misfolded aggregates in cerebrospinal fluid","volume":"74","author":"Shahnawaz","year":"2017","journal-title":"JAMA Neurol"},{"key":"10.3233\/JPD-230051_ref222","unstructured":"V-PLEX A\u03b2 Peptide Panel 1 (6E10) Kit, https:\/\/www.mesoscale.com\/en\/products\/v-plex-abeta-peptide-panel-1-6e10-kit-k15200e\/."},{"key":"10.3233\/JPD-230051_ref223","unstructured":"NEUROLOGY 3-PLEX A (TAU, A\u03b242, A\u03b240), https:\/\/www.quanterix.com\/simoa-assay-kits\/neurology-3-plex-tau-ab42-ab40\/."},{"key":"10.3233\/JPD-230051_ref224","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1002\/alz.12145","article-title":"First amyloid \u03b21-42 certified reference material for re-calibrating commercial immunoassays","volume":"16","author":"Boulo","year":"2020","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JPD-230051_ref225","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s13195-019-0517-9","article-title":"Towards a unified protocol for handling of CSF before \u03b2-amyloid measurements","volume":"11","author":"Janelidze","year":"2019","journal-title":"Alzheimers Res Ther"},{"key":"10.3233\/JPD-230051_ref226","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1080\/15622975.2017.1375556","article-title":"Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry","volume":"19","author":"Lewczuk","year":"2018","journal-title":"World J Biol Psychiatry"},{"key":"10.3233\/JPD-230051_ref227","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1007\/s00415-018-9100-8","article-title":"Amyloid-\u03b2 and Parkinson\u2019s disease","volume":"266","author":"Lim","year":"2019","journal-title":"J Neurol"},{"key":"10.3233\/JPD-230051_ref228","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1136\/jnnp.2009.199950","article-title":"CSF amyloid-\u03b2 and tau proteins, and cognitive performance, in early and untreated Parkinson\u2019s Disease: The Norwegian ParkWest study","volume":"81","author":"Alves","year":"2010","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.3233\/JPD-230051_ref229","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1212\/WNL.0000000000001098","article-title":"CSF biomarkers and clinical progression of Parkinson disease","volume":"84","author":"Hall","year":"2015","journal-title":"Neurology"},{"key":"10.3233\/JPD-230051_ref230","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/agm2.12192","article-title":"Salivary alpha-synuclein as a potential fluid biomarker in Parkinson\u2019s disease: A systematic review and meta-analysis","volume":"5","author":"Kharel","year":"2022","journal-title":"Aging Med"},{"key":"10.3233\/JPD-230051_ref231","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1002\/mds.29246","article-title":"Salivary \u03b1-Synuclein RT-QuIC correlates with disease severity in de novo Parkinson\u2019s disease","volume":"38","author":"Vivacqua","year":"2022","journal-title":"Mov Disord"},{"key":"10.3233\/JPD-230051_ref232","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.1093\/brain\/awad063","article-title":"Towards a multi-arm multi-stage platform trial of disease modifying approaches in Parkinson\u2019s disease","volume":"146","author":"Foltynie","year":"2023","journal-title":"Brain"},{"key":"10.3233\/JPD-230051_ref233","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(15)01037-5","article-title":"Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): Survival results from an adaptive, multiarm, multistage, platform randomised controlled trial","volume":"387","author":"James","year":"2016","journal-title":"Lancet"},{"key":"10.3233\/JPD-230051_ref234","unstructured":"U.S. Department of Health and Human Services Food and Drug Administration (2022) Patient-Focused Drug Development: Selecting, Developing, or Modifying Fit-for-Purpose Clinical Outcome Assessments."},{"key":"10.3233\/JPD-230051_ref235","unstructured":"European Medicines Agency, Guideline on clinical investigation of medicinal products in the treatment of Parkinson\u2019s disease (Revision 2), last updated July 6, 2012."},{"key":"10.3233\/JPD-230051_ref236","doi-asserted-by":"crossref","first-page":"e0269615","DOI":"10.1371\/journal.pone.0269615","article-title":"Connecting real-world digital mobility assessment to clinical outcomes for regulatory and clinical endorsement \u2013 the Mobilise-D study protocol","volume":"17","author":"Mikolaizak","year":"2022","journal-title":"PLoS One"},{"key":"10.3233\/JPD-230051_ref237","unstructured":"O\u2019Hanlon CE , Farmer CM , Ryan J , Ernecoff N (2023) Clinical Outcome Assessments and Digital Health Technologies Supporting Clinical Trial Endpoints in Early Parkinson\u2019s Disease: Roundtable Proceedings and Roadmap for Research RAND Corporation, Santa Monica, CA. https:\/\/www.rand.org\/pubs\/conf_proceedings\/CFA2550-1.html"}],"container-title":["Journal of Parkinson's Disease"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/JPD-230051","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,19]],"date-time":"2024-11-19T11:33:01Z","timestamp":1732015981000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.3233\/JPD-230051"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,8]]},"references-count":236,"journal-issue":{"issue":"6"},"URL":"https:\/\/doi.org\/10.3233\/jpd-230051","relation":{},"ISSN":["1877-7171","1877-718X"],"issn-type":[{"value":"1877-7171","type":"print"},{"value":"1877-718X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,8]]}}}